Kalaris Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell KLRS and other ETFs, options, and stocks.About KLRS
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases.
CEOAndrew Oxtoby
CEOAndrew Oxtoby
Employees6
Employees6
HeadquartersBerkeley Heights, New Jersey
HeadquartersBerkeley Heights, New Jersey
Founded
Founded
Employees6
Employees6
KLRS Key Statistics
Market cap142.14M
Market cap142.14M
Price-Earnings ratio-1.02
Price-Earnings ratio-1.02
Dividend yield—
Dividend yield—
Average volume134.90K
Average volume134.90K
High today$7.70
High today$7.70
Low today$7.10
Low today$7.10
Open price$7.11
Open price$7.11
Volume128.94K
Volume128.94K
52 Week high$12.90
52 Week high$12.90
52 Week low$2.14
52 Week low$2.14
Stock Snapshot
Kalaris Therapeutics(KLRS) stock is priced at $7.45, giving the company a market capitalization of 142.14M. It carries a P/E multiple of -1.02.
On 2025-12-11, Kalaris Therapeutics(KLRS) stock moved within a range of $7.10 to $7.70. With shares now at $7.45, the stock is trading +4.9% above its intraday low and -3.2% below the session's peak.
Trading volume for Kalaris Therapeutics(KLRS) stock has reached 128.94K, versus its average volume of 134.9K.
The stock's 52-week range extends from a low of $2.14 to a high of $12.90.
The stock's 52-week range extends from a low of $2.14 to a high of $12.90.
People also own
Based on the portfolios of people who own KLRS. This list is generated using Robinhood data, and it’s not a recommendation.